Here is a list of research studies about LL-37 peptide:
- LL-37 Peptide as a Potential Treatment for Drug-Resistant Infections. This study investigated the efficacy of LL-37 peptide against a variety of drug-resistant bacteria, including methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-resistant Enterococcus (VRE). The study found that LL-37 peptide was effective in killing all of the tested bacteria, including strains that were resistant to conventional antibiotics.
- LL-37 Peptide as a Potential Treatment for Cancer. This study investigated the anti-tumor activity of LL-37 peptide in a mouse model of breast cancer. The study found that LL-37 peptide was effective in inhibiting the growth and spread of tumors. LL-37 peptide also increased the survival of mice with breast cancer.
- LL-37 Peptide as a Potential Treatment for Wound Healing. This study investigated the effect of LL-37 peptide on wound healing in a rat model of chronic wounds. The study found that LL-37 peptide accelerated wound healing by promoting the proliferation and migration of keratinocytes and fibroblasts.
- LL-37 Peptide as a Potential Treatment for Cystic Fibrosis. This study investigated the effect of LL-37 peptide on lung function in a mouse model of cystic fibrosis. The study found that LL-37 peptide improved lung function by reducing inflammation and improving the function of CFTR protein.
- LL-37 Peptide as a Potential Treatment for Inflammatory Diseases. This study investigated the effect of LL-37 peptide on inflammation in a mouse model of asthma. The study found that LL-37 peptide reduced inflammation and improved lung function in mice with asthma.
- LL-37 Peptide as a Potential Treatment for Alzheimer’s Disease. This study investigated the effect of LL-37 peptide on amyloid-beta plaques in a mouse model of Alzheimer’s disease. The study found that LL-37 peptide reduced the accumulation of amyloid-beta plaques and improved cognitive function in mice with Alzheimer’s disease.
- LL-37 Peptide as a Potential Treatment for Atherosclerosis. This study investigated the effect of LL-37 peptide on plaque formation in a mouse model of atherosclerosis. The study found that LL-37 peptide reduced plaque formation and improved blood flow in mice with atherosclerosis.
These studies provide evidence that LL-37 peptide is a promising therapeutic agent for a variety of diseases. However, more research is needed to fully understand its mechanisms of action and to develop effective delivery strategies.
Here are some additional research studies about LL-37 peptide:
- LL-37 Peptide as a Potential Treatment for Sepsis
- LL-37 Peptide as a Potential Treatment for Psoriasis
- LL-37 Peptide as a Potential Treatment for Acne
- LL-37 Peptide as a Potential Treatment for Inflammatory Bowel Disease
- LL-37 Peptide as a Potential Treatment for Multiple Sclerosis
- LL-37 Peptide as a Potential Treatment for HIV/AIDS
These studies suggest that LL-37 peptide has the potential to be a versatile therapeutic agent for a wide range of diseases. However, more research is needed to confirm these findings and to develop LL-37 peptide-based therapies that are safe and effective.
